Home  »  Company   »  After A 12.08% Jump In The Last Week, Does Lexicon...

After A 12.08% Jump In The Last Week, Does Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) Still Make Sense To Buy?

During the last session, Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)’s traded shares were 2.0 million, with the beta value of the company hitting 1.50. At the end of the trading day, the stock’s price was $2.69, reflecting an intraday loss of 0.00% or $0.0. The 52-week high for the LXRX share is $6.33, that puts it down -135.32 from that peak though still a striking 51.3% gain since the share price plummeted to a 52-week low of $1.31. The company’s market capitalization is $552.93M, and the average intraday trading volume over the past 10 days was 2.11 million shares, and the average trade volume was 1.47 million shares over the past three months.

Lexicon Pharmaceuticals Inc. (LXRX) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.30. LXRX has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.16.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) trade information

Lexicon Pharmaceuticals Inc. (LXRX) registered a 0.00% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet 0.00% in intraday trading to $2.69 this Thursday, 08/04/22, hitting a weekly high. The stock’s 5-day price performance is 12.08%, and it has moved by 2.28% in 30 days. Based on these gigs, the overall price performance for the year is -21.11%. The short interest in Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is 8.24 million shares and it means that shorts have 2.95 day(s) to cover.

The consensus price target of analysts on Wall Street is $9.30, which implies an increase of 71.08% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.60 and $16.00 respectively. As a result, LXRX is trading at a discount of -494.8% off the target high and 3.35% off the low.

Lexicon Pharmaceuticals Inc. (LXRX) estimates and forecasts

Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -23.10% this quarter and then jump 12.50% in the quarter after that. In the rating firms’ projections, revenue will decrease -63.10% compared to the previous financial year.

Revenue for the current quarter is expected to be $50k as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to $50k by the end of Sep 2022.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 13.80%. While earnings are projected to return -14.00% in 2022.

LXRX Dividends

Lexicon Pharmaceuticals Inc. is due to release its next quarterly earnings between March 08 and March 14. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)’s Major holders

Lexicon Pharmaceuticals Inc. insiders own 4.15% of total outstanding shares while institutional holders control 83.63%, with the float percentage being 87.25%. Artal Group S.A. is the largest shareholder of the company, while 156 institutions own stock in it. As of Mar 30, 2022, the company held over 71.18 million shares (or 47.58% of all shares), a total value of $148.76 million in shares.

The next largest institutional holding, with 14.36 million shares, is of BVF Inc.’s that is approximately 9.60% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $30.01 million.

Also, the Mutual Funds coming in first place with the largest holdings of Lexicon Pharmaceuticals Inc. (LXRX) shares are Vanguard Total Stock Market Index Fund and Fidelity Growth Company Fund. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 2.12 million shares. This amounts to just over 1.42 percent of the company’s overall shares, with a $4.43 million market value. The same data shows that the other fund manager holds slightly less at 1.92 million, or about 1.28% of the stock, which is worth about $3.39 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts